{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-035499","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.639723+00:00","generated_at":"2026-05-15T08:33:02.609818+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve equity plan increase at 2026 annual meeting","bullets":["All 11 incumbent directors re-elected with overwhelming support (over 98% for each nominee).","Ratification of Simon & Edward, LLP as independent auditor for FY 2026: 10,597,352 for, 12,291 against.","Equity incentive plan increase approved: 9,964,400 for, 643,419 against; shares reserved now 15% of outstanding.","Quorum established with 10,612,493 shares (41.74% of voting power) present."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-035499","json":"https://secwatch.observer/filing/0001213900-26-035499.json","markdown":"https://secwatch.observer/filing/0001213900-26-035499.md","text":"https://secwatch.observer/filing/0001213900-26-035499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390026035499/0001213900-26-035499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390026035499/ea028361801-8k_abvcbiopharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:33:02.609818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}